PROSPECTIVE RANDOMIZED TRIAL OF EFFICACY OF GANCICLOVIR VERSUS THAT OF ANTICYTOMEGALOVIRUS (CMV) IMMUNOGLOBULIN TO PREVENT CMV DISEASE IN CMV-SEROPOSITIVE HEART-TRANSPLANT RECIPIENTS TREATED WITH OKT3

被引：32

作者：

AGUADO, JM

GOMEZSANCHEZ, MA

LUMBRERAS, C

DELGADO, J

LIZASOAIN, M

OTERO, JR

RUFILANCHAS, JJ

NORIEGA, AR

机构：

[1] HOSP DOCE OCTUBRE,DEPT MICROBIOL,INFECT DIS UNIT,E-28041 MADRID,SPAIN

[2] HOSP DOCE OCTUBRE,DEPT MICROBIOL,VIROL UNIT,E-28041 MADRID,SPAIN

[3] HOSP DOCE OCTUBRE,DEPT CARDIOL,E-28041 MADRID,SPAIN

[4] HOSP DOCE OCTUBRE,DEPT CARDIAC SURG,E-28041 MADRID,SPAIN

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1995年 / 39卷 / 07期

关键词：

D O I：

10.1128/AAC.39.7.1643

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We compared the efficacy of ganciclovir versus that of cytomegalovirus (CMV) immunoglobulin for the prevention of CMV disease in 31 CMV-seropositive heart transplant recipients, who had received early immunoprophylaxis with OKT3 monoclonal antibodies. The incidence of CMV disease and visceral involvement uas much higher in the CMV immunoglobulin group than in the ganciclovir group (40 versus 6%, respectively; P = 0.03). No adverse effects were found in the CMV immunoglobulin group, but 19% of the patients in the ganciclovir group developed mild leukopenia or a mild increase in their serum creatinine levels.

引用

页码：1643 / 1645

页数：3

共 11 条

[1]

AGUADO JM, 1992, 32ND INT C ANT AG CH, P295

[2] PASSIVE-IMMUNIZATION AGAINST CYTOMEGALOVIRUS IN ALLOGRAFT RECIPIENTS - THE ROTTERDAM HEART-TRANSPLANT PROGRAM EXPERIENCE [J].

BALK, AHMM ;

WEIMAR, W ;

ROTHBARTH, PH ;

MEETER, K ;

METSELAAR, HJ ;

MOCHTAR, B ;

SIMOONS, ML .

INFECTION, 1993, 21 (04) :195-200

[3]

EISENMANN D, 1990, TRANSPLANT P, V22, P2322

[4]

GLOWACKI LS, 1994, CLIN TRANSPLANT, V8, P10

[5]

HAVEL M, 1990, TRANSPLANT P, V22, P1805

[6] SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL-TRANSPLANT RECIPIENT TREATED WITH OKT3 [J].

HIBBERD, PL ;

TOLKOFFRUBIN, NE ;

COSIMI, AB ;

SCHOOLEY, RT ;

ISAACSON, D ;

DORAN, M ;

DELVECCHIO, A ;

DELMONICO, FL ;

AUCHINCLOSS, H ;

RUBIN, RH .

TRANSPLANTATION, 1992, 53 (01) :68-72

[7]

JESPERSEN DJ, 1985, J CLI MICROBIOL, V21, P217

[8] GANCICLOVIR PROPHYLAXIS DECREASES FREQUENCY AND SEVERITY OF CYTOMEGALOVIRUS DISEASE IN SEROPOSITIVE LIVER-TRANSPLANT RECIPIENTS TREATED WITH OKT3 MONOCLONAL-ANTIBODIES [J].

LUMBRERAS, C ;

OTERO, JR ;

HERRERO, JA ;

GOMEZ, R ;

LIZASOAIN, M ;

AGUADO, JM ;

COLINA, F ;

GARCIA, I ;

MORENO, E ;

NORIEGA, AR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2490-2492

[9] A CONTROLLED TRIAL OF GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER HEART-TRANSPLANTATION [J].

MERIGAN, TC ;

RENLUND, DG ;

KEAY, S ;

BRISTOW, MR ;

STARNES, V ;

OCONNELL, JB ;

RESTA, S ;

DUNN, D ;

GAMBERG, P ;

RATKOVEC, RM ;

RICHENBACHER, WE ;

MILLAR, RC ;

DUMOND, C ;

DEAMOND, B ;

SULLIVAN, V ;

CHENEY, T ;

BUHLES, W ;

STINSON, EB .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (18) :1182-1186

[10]

REYNOLDS DW, 1979, DIAGNOSTIC PROCEDURE, P399

← 1 2 →